Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Endothelins and their receptors in cancer: identification of therapeutic targets.

Wang R, Dashwood RH.

Pharmacol Res. 2011 Jun;63(6):519-24. doi: 10.1016/j.phrs.2011.01.002. Epub 2011 Jan 18. Review.

2.

The endothelin axis in cancer.

Bagnato A, RosanĂ² L.

Int J Biochem Cell Biol. 2008;40(8):1443-51. doi: 10.1016/j.biocel.2008.01.022. Epub 2008 Feb 1. Review.

PMID:
18325824
3.

The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy.

Bagnato A, Spinella F, RosanĂ² L.

Can J Physiol Pharmacol. 2008 Aug;86(8):473-84. doi: 10.1139/Y08-058. Review.

4.

The endothelin axis: emerging role in cancer.

Nelson J, Bagnato A, Battistini B, Nisen P.

Nat Rev Cancer. 2003 Feb;3(2):110-6. Review.

PMID:
12563310
5.

A review of the profile of endothelin axis in cancer and its management.

Irani S, Salajegheh A, Smith RA, Lam AK.

Crit Rev Oncol Hematol. 2014 Feb;89(2):314-21. doi: 10.1016/j.critrevonc.2013.08.011. Epub 2013 Sep 4. Review.

PMID:
24035584
6.

Targeting endothelin axis in cancer.

Bagnato A, Natali PG.

Cancer Treat Res. 2004;119:293-314. Review. No abstract available.

PMID:
15164883
7.

Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.

Thakkar SG, Choueiri TK, Garcia JA.

Curr Oncol Rep. 2006 Mar;8(2):108-13.

PMID:
16507220
8.

Endothelin receptor antagonism and cancer.

Bhalla A, Haque S, Taylor I, Winslet M, Loizidou M.

Eur J Clin Invest. 2009 Jun;39 Suppl 2:74-7. doi: 10.1111/j.1365-2362.2009.02123.x. Review. Erratum in: Eur J Clin Invest. 2009 Jul;39(7):630.

PMID:
19335749
9.

Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology.

Rubanyi GM, Polokoff MA.

Pharmacol Rev. 1994 Sep;46(3):325-415. Review. No abstract available.

PMID:
7831383
10.

Endothelins in health and disease: an overview.

Goldie RG.

Clin Exp Pharmacol Physiol. 1999 Feb;26(2):145-8. Review.

PMID:
10065336
11.

California dreamin' 'bout endothelin: emerging new therapeutics.

Warner TD, Elliott JD, Ohlstein EH.

Trends Pharmacol Sci. 1996 May;17(5):177-81.

PMID:
8669122
12.

The Twelfth International Conference on Endothelin (ET-12), Cambridge 2011.

Barton M, Davenport AP.

Life Sci. 2012 Oct 15;91(13-14):462-5. doi: 10.1016/j.lfs.2012.07.015. Epub 2012 Jul 26.

13.

Anti-endothelin drugs in solid tumors.

Russo A, Bronte G, Rizzo S, Fanale D, Di Gaudio F, Gebbia N, Bazan V.

Expert Opin Emerg Drugs. 2010 Mar;15(1):27-40. doi: 10.1517/14728210903571667. Review.

PMID:
20102289
14.

New perspectives on the endothelin axis in pain.

Barr TP, Kam S, Khodorova A, Montmayeur JP, Strichartz GR.

Pharmacol Res. 2011 Jun;63(6):532-40. doi: 10.1016/j.phrs.2011.02.002. Epub 2011 Feb 23. Review. No abstract available.

15.

Endothelins--from receptors to medicine.

Miller RC, Pelton JT, Huggins JP.

Trends Pharmacol Sci. 1993 Feb;14(2):54-60. Review.

PMID:
8480375
16.

Pharmacological potential of endothelin receptors agonists and antagonists.

Patocka J, Merka V, Hrdina V, Hrdina R.

Acta Medica (Hradec Kralove). 2005;48(2):67-73. Review.

17.
18.

Endothelin receptor antagonists as therapeutic agents for cancer.

Wu-Wong JR.

Curr Opin Investig Drugs. 2002 Aug;3(8):1234-9. Review.

PMID:
12211422
19.

[Endothelin receptor and intracellular signaling].

Hara J, Sakurai T.

Nihon Rinsho. 2004 Sep;62 Suppl 9:588-90. Review. Japanese. No abstract available.

PMID:
15506453
20.

Molecular pharmacology and pathophysiological significance of endothelin.

Goto K, Hama H, Kasuya Y.

Jpn J Pharmacol. 1996 Dec;72(4):261-90. Review.

Supplemental Content

Support Center